CIR Model For Ingredient Assessment Piques China's Interest
This article was originally published in The Rose Sheet
Regulatory authorities in developing countries, including China, are showing increasing interest in the Cosmetic Ingredient Review process, with a view to adapting it for use in their own regions, according to CIR Director Lillian Gill.
You may also be interested in...
Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.
In reports accompanying draft fiscal 2016 funding bills, both House and Senate committees recommend that FDA work with industry to explore formalizing the Cosmetic Ingredient Review via a public-private partnership similar to that in place with the U.S. Pharmacopeial Convention.
Marketers of cosmetic products that rely on prostaglandins or their analogues to grow eyelashes – or compete against companies that use the ingredients – have until 22 October to submit information to the Commission, which will help inform an assessment by the Scientific Committee on Consumer Safety.